{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:40:05Z","timestamp":1770446405262,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jaad.2016.01.037","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T06:59:36Z","timestamp":1458370776000},"page":"1066-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-0534","authenticated-orcid":false,"given":"Eva","family":"Vilarrasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Notario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Bordas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi J.","family":"Gich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2016.01.037_bib1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.12543","article-title":"Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish center","volume":"169","author":"L\u00f3pez-Ferrer","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.01.037_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0001-7310(09)71257-8","article-title":"Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents","volume":"100","author":"Puig","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2016.01.037_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2016.01.037_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jdv.12494","article-title":"Treatment patterns with topicals, traditional systemics and biologics in psoriasis\u2013a Swedish database analysis","volume":"29","author":"Svedbom","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2016.01.037_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bjd.13087","article-title":"\u2018Happy\u2019 drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network","volume":"171","author":"van den Reek","year":"2014","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2016.01.037_bib6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12353","article-title":"Drug survival rates in patients with psoriasis after treatment with biologics","volume":"40","author":"Umezawa","year":"2013","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2016.01.037_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.2011.10557.x","article-title":"Drug survival rates of biologic treatments in patients with psoriasis vulgaris","volume":"166","author":"Brunasso","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2016.01.037_bib8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09546634.2011.593489","article-title":"Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis","volume":"23","author":"Di Lernia","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.037_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of antitumor necrosis factor-\u03b1 treatments for psoriasis in routine dermatological practice: a multicenter observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.01.037_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.037_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2340\/00015555-1230","article-title":"Dose-creep of infliximab during psoriasis treatment: an observational study","volume":"92","author":"Mehren","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2016.01.037_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.037_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjd.13001","article-title":"Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-center database analysis","volume":"171","author":"Menting","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2016.01.037_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.01.037_bib15","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. CHMP\/EWP\/2454\/02 corr. (2004, November 18). Available from: URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003329.pdf. Accessed January 2015."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216001171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216001171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:16Z","timestamp":1759271956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216001171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0190962216001171"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.037","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}